Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FLXN

Flexion Therapeutics (FLXN) Stock Price, News & Analysis

Flexion Therapeutics logo

About Flexion Therapeutics Stock (NASDAQ:FLXN)

Advanced Chart

Key Stats

Today's Range
$25.32
$25.37
50-Day Range
$9.12
$9.44
52-Week Range
$4.30
$13.66
Volume
2,040 shs
Average Volume
1.18 million shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FLXN Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
VIRI Virios Therapeutics, Inc.
Spyre Therapeutics Inc SYRE
PFIZER INC's Net Worth
See More Headlines

FLXN Stock Analysis - Frequently Asked Questions

Flexion Therapeutics, Inc. (NASDAQ:FLXN) released its earnings results on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.08. The specialty pharmaceutical company had revenue of $24.59 million for the quarter, compared to analyst estimates of $24.61 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), NVIDIA (NVDA), Gilead Sciences (GILD), Bristol Myers Squibb (BMY), Lipocine (LPCN), Micron Technology (MU) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
5/12/2021
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FLXN
CIK
1419600
Employees
257
Year Founded
2007

Profitability

EPS (Trailing Twelve Months)
($2.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$113.71 million
Net Margins
-100.32%
Pretax Margin
-100.32%
Return on Equity
N/A
Return on Assets
-44.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.38
Quick Ratio
4.05

Sales & Book Value

Annual Sales
$85.55 million
Price / Sales
14.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.34) per share
Price / Book
-74.62

Miscellaneous

Outstanding Shares
50,321,000
Free Float
45,727,000
Market Cap
$1.28 billion
Optionable
No Data
Beta
1.53

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:FLXN) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners